老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
iShares Health Innovation Active ETF
33.56
+0.2459
0.74%
成交量:
528
成交額:
1.77萬
市值:
1,342.44萬
市盈率:
- -
高:
33.56
開:
33.41
低:
33.41
收:
33.32
52周最高:
34.86
52周最低:
25.79
股本:
40.00萬
流通股本:
40.00萬
量比:
0.45
換手率:
0.13%
股息:
0.08
股息率:
0.24%
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
長風藥業(02652)續漲3.76% ICF001拿到三項臨床試驗默示許可
金吾财讯
·
09/14
強生Rybrevant聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現迄今報告最長的中位總生存期
美股速递
·
09/14
強生:RYBREVANT聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現已報告的最長中位總生存期。
智通财经
·
09/14
強生據報與阿波羅洽談約200億美元骨科業務交易
环球市场播报
·
09/13
傳阿波羅(APO.US)擬接盤強生(JNJ.US)骨科業務 潛在交易估值近200億美元
智通财经
·
09/12
據彭博社報導,阿波羅全球正就收購強生公司骨科業務部門進行談判
路透中文
·
09/12
據彭博社報道,阿波羅全球正就收購強生公司骨科業務部門進行談判
路透中文
·
09/12
據稱阿波羅正在洽談收購強生骨科業務部門。
智通财经
·
09/12
美國食品藥品監督管理局(FDA)批准了Scholar Rock公司的一款治療肌肉無力症的藥物
路透中文
·
09/12
阿斯利康:SERENA-4臨床試驗未達到主要終點。
智通财经
·
09/12
美國股市動態
路透中文
·
09/12
興齊眼藥(300573.SZ):SQ-23082滴眼液獲批開展臨床試驗
智通财经
·
09/11
興齊眼藥:SQ-23082獲臨床試驗批准,屬2.1類
智通财经
·
09/11
強生(JNJ)漲1.63% 新款雙周拋隱形眼鏡獲CE認證
金吾财讯
·
09/10
翰宇藥業(300199.SZ):HY3003注射液臨床試驗申請獲受理
智通财经
·
09/10
默沙東帕博利珠單抗三陰性乳腺癌適應症人群擴展在華獲批
智通财经
·
09/10
翰宇藥業:HY3003注射液獲臨床試驗申請受理通知書
智通财经
·
09/10
英硅智能(03696):公司管線中領先的人工智能驅動候選創新藥物 Rentosertib已在針對特發性肺纖維化的III期臨床試驗中完成首例患者入組
智通财经
·
09/10
拜耳啓動G蛋白偶聯內流整流鉀通道4研究性抑制劑針對心房顫動患者的II期臨床試驗。
智通财经
·
09/09
Leerink Partners上調默克目標價至161美元
格隆汇
·
09/09
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BMED/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":33.5609,"timestamp":1789588800000,"preClose":33.315,"halted":0,"volume":528,"delay":0,"changeRate":0.007381059582770491,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"盤前交易","change":0.2459,"latestTime":"09-17 05:34:48 EDT","open":33.41,"high":33.5609,"low":33.41,"amount":17687,"amplitude":0.004529,"askPrice":53.36,"askSize":100,"bidPrice":13.5,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":33.5609,"sharesOutstanding":360000,"nav":33.339378,"aum":13335751.2,"dividendRate":0.002375,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.41,"preClose":33.5609,"latestTime":"16:10 EDT","volume":6,"amount":201.3654,"timestamp":1789589403907,"change":-0.1509,"changeRate":-0.004496,"amplitude":0},"volumeRatio":0.4498977160098888,"impliedVol":0.0628,"impliedVolPercentile":0.004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4498977160098888,"shares":400000,"dividePrice":0.0797,"high":33.5609,"amplitude":0.004529,"preClose":33.315,"low":33.41,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":33.5609,"eps":0,"divideRate":0.002375,"volume":528,"delay":0,"ttmEps":0,"open":33.41,"prevYearClose":30.32,"prevWeekClose":32.965,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":33.0422,"twentyDayClose":32.666,"sixtyDayClose":28.5621},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667631770","title":"長風藥業(02652)續漲3.76% ICF001拿到三項臨床試驗默示許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631770","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667631770?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 10:16","pubTimestamp":1789352216,"startTime":"0","endTime":"0","summary":"金吾财讯 | 长风药业(02652)股价扬升,续涨3.76%,报10.75港元,成交额3166万港元。消息面上,长风药业自研创新药长效吸入粉雾剂ICF001接连拿到三项临床试验默示许可。截至目前,这款候选药物已覆盖PAH、PH-ILD、IPF、PPF四大适应症,也是国内首家将该类长效吸入前药推进至国内临床试验阶段的企业。公司董事长兼执行董事梁文青博士称,将同步开展海内外I期临床,积极布局海外合作开发、区域授权等全球化商业化路径。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991472","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","PSYK","MDTX","BMED","02652","IBBQ","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120093998","title":"強生Rybrevant聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現迄今報告最長的中位總生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1120093998","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120093998?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:47","pubTimestamp":1789350464,"startTime":"0","endTime":"0","summary":"强生公司日前公布了一项重磅临床数据——其旗下药物Rybrevant与化疗联用,在携带EGFR外显子20插入突变的非小细胞肺癌患者中,取得了目前公开报告中最长的中位总生存期。EGFR外显子20插入突变,历来被视为治疗难点,可选方案有限且疗效欠佳。观察人士指出,这不仅能巩固Rybrevant在精准医疗版图中的地位,更可能重塑晚期非小细胞肺癌的一线治疗格局。强生能否借此在竞争激烈的肺癌药物市场中进一步扩大优势,值得持续跟踪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2129689431.USD","LU2456880835.USD","LU1244550494.USD","LU0345769631.USD","LU1121112475.USD","LU1629891620.HKD","IE00B7SZLL34.SGD","LU1778281490.HKD","IE00BSNM7G36.USD","LU0320765646.SGD","LU1066051498.USD","LU1066051811.HKD","LU2133065610.SGD","LU0289961442.SGD","SG9999002232.USD","IE000M9KFDE8.USD","LU2236285917.USD","IE00BZ1G4Q59.USD","LU1196500208.SGD","IE000SO60NU8.SGD","BK4588","IE0034235303.USD","LU0545562505.USD","BMED","IE000WAW04H5.SGD","LU1430594728.SGD","BK4504","LU0210536198.USD","LU2471134523.USD","BK4533","BK4581","TRUH","LU2403377893.USD","LU2417539215.USD","LU1066051225.USD","LU2129689605.HKD","IE00BJJMRZ35.SGD","LU0795875169.SGD","LU1989771016.USD","IE00B19Z3581.USD","LU1929549753.HKD","LU1145028129.USD","LU1228905540.USD","IXJ","LU1057294990.SGD","JNJ","LU0994945656.USD","LU2213496289.HKD","LU0795875086.SGD","SG9999001440.SGD","IE00B2B36J28.USD","LU2430703095.HKD","LU1551013425.SGD","LU2756315318.SGD","LU0792757196.USD","IE00B19Z3B42.SGD","IE00BFXG1179.USD","LU0345769128.USD","LU1074936037.SGD","LU2487616109.SGD","LU0070217475.USD","LU1718418525.SGD","LU0640476718.USD","LU1032955483.USD","BK4007","IE00BLSP4239.USD","LU0057025933.USD","IE0002270589.USD","LU1674673428.USD","LU1244550221.USD","IE00BGHQF631.EUR","LU2023250330.USD","IE00BVYPNV92.GBP","LU0203345920.USD","LU1267930813.SGD","LU0466842654.USD","LU1221951129.SGD","IE000F7OJYX1.SGD","LU2756315664.SGD","LU0345770993.USD","LU0114720955.EUR","IE00B3PB1722.GBP","LU0426412945.USD","IE000MB6IJN5.SGD","SGXZ80539844.SGD","LU0820561818.USD","LU1674673691.USD","LU1914381329.SGD","LU2430703251.USD","LU2592432038.USD","LU0345770308.USD","LU1894683348.USD","LU0472753341.HKD","RXL","LU0689472784.USD","LU0124676726.USD","BK4550","LU0882574055.USD","SG9999001176.SGD","IE00BKVL7J92.USD","LU0426417589.USD","LU1244550577.SGD","LU1732800096.USD","IE00BBT3K403.USD","LU1162221912.USD","LU0122379950.USD","LU0964807845.USD","LU1221951046.USD","LU1059921491.USD","VHT","LU1506573853.SGD","IE000BZT7R73.USD","LU1061106388.HKD","LU2602419157.SGD","BK4534","IE00BN8TJ469.HKD","BK4585","IE00BDGV0183.EUR","LU0820561909.HKD","LU0069063385.USD","IE00BFTCPJ56.SGD","BK4532","SG9999013999.USD","LU0203347892.USD","LU1228905037.USD","BK4559","LU0098860793.USD","LU0787776722.HKD","LU1585245621.USD","LU2089984988.USD","MEDX","LU1935042991.SGD","LU0432979614.USD","IE00B1BXHZ80.USD","IE0001KFT4U8.USD","LU1032466523.USD","IYH","LU0820562030.AUD","LU1983299246.USD","LU0289739699.SGD","LU1894683264.USD","SGXZ57979304.SGD","LU0689626769.HKD","LU0053666078.USD","IE00BJT1NW94.SGD","LU0683600562.USD","IE00B42XCP33.USD","LU0889566641.SGD","LU0162691827.USD","LU2347655156.SGD","IE00B3T34201.USD","LU1043141123.HKD","JDOC","IE00BVYPNW00.USD","LU1066053197.SGD","LU0943347566.SGD","IHE","LU0058720904.USD","LU2468319806.SGD","LU1551013342.USD","FTXH","GDOC","IE0000B7K699.USD","LU0912757837.SGD","LU2471134879.HKD","LU0234570918.USD","LU1280957306.USD","LU1732799900.SGD","LU1496350502.SGD","LU2471134952.CNY","LU2505996681.GBP","LU1043141396.HKD","BK4568","LU0234572021.USD","FHLC","IE00BLSP4452.SGD","LU0289739343.SGD","LU0210528500.USD","IE0002141913.USD","LU2471134796.USD","XLV","SG9999001176.USD","LU2129689514.USD","LU2112291526.USD","LU2896262040.SGD","LU2505996509.AUD","LU1023059063.AUD","LU1261432733.SGD","LU2430703178.SGD","IE00B4R5TH58.HKD","LU2750360641.GBP","LU0985320562.USD","LU1291159041.SGD","BK4592","SG9999002224.SGD","LU0511384066.AUD","LU0072461881.USD","PJP","LU2750360997.AUD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631840","title":"強生:RYBREVANT聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現已報告的最長中位總生存期。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667631840?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:46","pubTimestamp":1789350398,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IXJ","LU1145028129.USD","BK4550","IE00BLSP4239.USD","GDOC","LU0683600562.USD","LU0053666078.USD","BK4568","BMED","FHLC","LU0511384066.AUD","LU2471134523.USD","BK4559","FTXH","IE00BGHQF631.EUR","XLV","IE00BFTCPJ56.SGD","IYH","LU2471134879.HKD","MEDX","LU1244550494.USD","BK4533","IE00BDGV0183.EUR","LU0122379950.USD","TRUH","LU0985320562.USD","LU2133065610.SGD","JNJ","LU1032466523.USD","LU1674673691.USD","BK4588","LU0820561909.HKD","IHE","LU1894683264.USD","IE0002141913.USD","RXL","IE0000B7K699.USD","IE00BVYPNV92.GBP","PJP","IE0001KFT4U8.USD","IE00B3T34201.USD","LU2592432038.USD","LU1935042991.SGD","JDOC","LU2089984988.USD","LU2430703095.HKD","LU1280957306.USD","VHT","LU0426417589.USD","LU0072461881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667329689","title":"強生據報與阿波羅洽談約200億美元骨科業務交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2667329689","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667329689?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 14:27","pubTimestamp":1789280820,"startTime":"0","endTime":"0","summary":"据知情人士消息,阿波罗全球管理公司正洽谈收购强生旗下以DePuy Synthes为主体的骨科业务,交易金额约为200亿美元。知情人士称,强生与阿波罗正在就出售展开谈判,但双方仍可能无法达成交易,强生也可能选择其他买家。强生和阿波罗目前均未公布交易安排。以当前报道的约200亿美元交易金额计算,潜在售价与强生当年的实际收购价格大致相当,但期间业务范围、财务表现和资产构成已经发生变化。此次潜在出售也是强生持续调整业务组合的一部分。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-13/doc-inirskha4546532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1066053197.SGD","PJP","LU2471134523.USD","LU1778281490.HKD","LU1430594728.SGD","LU0122379950.USD","LU2129689431.USD","LU1059921491.USD","LU0795875169.SGD","LU2456880835.USD","FHLC","LU1732800096.USD","IYH","LU2213496289.HKD","LU1496350502.SGD","LU0545562505.USD","LU0057025933.USD","LU0820561909.HKD","JDOC","GDOC","IE0009355771.USD","LU0889566641.SGD","LU0689472784.USD","IE000F7OJYX1.SGD","LU1935042991.SGD","LU2023250330.USD","VHT","XLV","LU0792757196.USD","BMED","MEDX","IE00B4R5TH58.HKD","LU1228905540.USD","TRUH","LU0795875086.SGD","IHE","LU0426412945.USD","LU0640476718.USD","IE00BVYPNV92.GBP","FTXH","JNJ","IE00B42XCP33.USD","IXJ","IE00BFXG1179.USD","LU1074936037.SGD","LU2430703251.USD","LU2896262040.SGD","RXL","LU2089984988.USD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666508051","title":"傳阿波羅(APO.US)擬接盤強生(JNJ.US)骨科業務 潛在交易估值近200億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666508051","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666508051?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 11:04","pubTimestamp":1789182275,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,据媒体援引知情人士消息报道,全球另类资产管理公司阿波罗全球管理 正洽谈收购强生的骨科业务部门DePuy Synthes。这笔交易对该业务的估值可能接近200亿美元。强生的骨科业务部门DePuy Synthes主要生产关节植入物和手术器械,2025年创造了93亿美元的收入,但收入增速仅为1.1%。相比之下,强生2025年整体营收同比增长6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FHLC","GDOC","MEDX","IYH","IXJ","JNJ","LU1267930813.SGD","LU2112291526.USD","IE00BGHQF631.EUR","LU1162221912.USD","LU2602419157.SGD","LU1506573853.SGD","IHE","APO","BMED","LU0345769631.USD","VHT","LU0689626769.HKD","LU2471134796.USD","LU0545562505.USD","LU1066051498.USD","IE00B3T34201.USD","RXL","XLV","IE00B42XCP33.USD","IE0001KFT4U8.USD","LU0912757837.SGD","LU1989771016.USD","LBO","LU1244550494.USD","LU2468319806.SGD","LU2487616109.SGD","TRUH","LU2471134523.USD","PRVT","IE000F7OJYX1.SGD","LU0006061336.USD","LU1057294990.SGD","LU1032466523.USD","BK4585","FTXH","JDOC","LU2129689431.USD","PJP","LU2756315318.SGD","GPZ","LU1668664300.SGD","IE000BZT7R73.USD","IE00B775SV38.USD","AAUM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666778075","title":"據彭博社報導,阿波羅全球正就收購強生公司骨科業務部門進行談判","url":"https://stock-news.laohu8.com/highlight/detail?id=2666778075","media":"路透中文","labels":["corporation","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666778075?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 06:42","pubTimestamp":1789166537,"startTime":"0","endTime":"0","summary":"据彭博社报导,阿波罗全球正就收购强生公司骨科业务部门进行谈判路透9月11日-据彭博社周五援引消息人士报导,阿波罗全球管理公司(Apollo Global Management,APO.N)正在就收购强生公司(Johnson & JohnsonJNJ.N)旗下骨科业务部门进行磋商,该交易可能使该业务部门的估值接近200亿美元。路透无法立即核实该报导。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4T4531JU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNW00.USD","LU1228905540.USD","LU0345770993.USD","IE00BGHQF631.EUR","VHT","LU0114720955.EUR","LU0795875086.SGD","IYH","BK4592","LU1551013342.USD","AAUM","LU2347655156.SGD","IXJ","LU1323610961.USD","BMED","FTXH","LU1929549753.HKD","JDOC","TRUH","LU1668664300.SGD","RXL","IHE","GDOC","LU0234572021.USD","BK4588","LU1430594728.SGD","FHLC","LU1066051498.USD","LU1221951046.USD","LU2129689514.USD","LU0122379950.USD","LU2487616109.SGD","LU0985320562.USD","IE00BSNM7G36.USD","PRVT","LU2750360641.GBP","APO","PJP","XLV","JNJ","GPZ","LU2471134523.USD","MEDX","LU1032955483.USD","LU1778281490.HKD","BK4007","LU1585245621.USD","LU0203347892.USD","LBO","LU2112291526.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666577802","title":"據彭博社報道,阿波羅全球正就收購強生公司骨科業務部門進行談判","url":"https://stock-news.laohu8.com/highlight/detail?id=2666577802","media":"路透中文","labels":["corporation","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666577802?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 06:42","pubTimestamp":1789166537,"startTime":"0","endTime":"0","summary":"据彭博社报道,阿波罗全球正就收购强生公司骨科业务部门进行谈判路透9月11日-据彭博社周五援引消息人士报道,阿波罗全球管理公司(Apollo Global Management,APO.N)正在就收购强生公司(Johnson & JohnsonJNJ.N)旗下骨科业务部门进行磋商,该交易可能使该业务部门的估值接近200亿美元。路透无法立即核实该报道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4S4531JU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VHT","IE00BKVL7J92.USD","LU2505996509.AUD","IXJ","XLV","LU0882574055.USD","BK4585","LU0964807845.USD","LU2112291526.USD","LU1196500208.SGD","LBO","LU0820562030.AUD","LU1506573853.SGD","RXL","LU1629891620.HKD","LU2756315664.SGD","LU0234570918.USD","LU1059921491.USD","AAUM","LU1935042991.SGD","LU1894683264.USD","FHLC","BMED","JNJ","LU1261432733.SGD","IE000F7OJYX1.SGD","BK4007","LU1989771016.USD","SG9999001176.USD","LU1221951129.SGD","LU1228905540.USD","TRUH","LU0792757196.USD","PJP","IHE","JDOC","MEDX","IE00BFXG1179.USD","PRVT","LU1043141396.HKD","GPZ","GDOC","IE00BGHQF631.EUR","BK4504","IYH","APO","LU0203345920.USD","IE000M9KFDE8.USD","FTXH","IE000MB6IJN5.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666657206","title":"據稱阿波羅正在洽談收購強生骨科業務部門。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666657206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666657206?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 06:25","pubTimestamp":1789165559,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2750360997.AUD","IXJ","LU0289739699.SGD","LU2756315664.SGD","IE00BZ1G4Q59.USD","LU0640476718.USD","LU0787776722.HKD","SGXZ57979304.SGD","LU1061106388.HKD","IE0000B7K699.USD","IE00BGHQF631.EUR","LU0689472784.USD","SG9999001176.USD","LU2468319806.SGD","VHT","XLV","IHE","LU0795875086.SGD","JDOC","IYH","PJP","TRUH","IE000WAW04H5.SGD","LU1066051498.USD","LU1244550221.USD","SG9999001440.SGD","IE000SO60NU8.SGD","LU0345770308.USD","LU2133065610.SGD","LU2213496289.HKD","SGXZ80539844.SGD","LU0985320562.USD","LU1057294990.SGD","LU0943347566.SGD","LU0964807845.USD","LU0820562030.AUD","FTXH","LU1221951046.USD","IE00BFXG1179.USD","LU0345770993.USD","IE00B1BXHZ80.USD","LU2487616109.SGD","RXL","LU0210536198.USD","GDOC","LU1732800096.USD","JNJ","FHLC","MEDX","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666257258","title":"美國食品藥品監督管理局(FDA)批准了Scholar Rock公司的一款治療肌肉無力症的藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2666257258","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666257258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 05:25","pubTimestamp":1789161915,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局(FDA)批准了Scholar Rock公司的一款治疗肌肉无力症的药物路透9月11日-美国食品和药物管理局(FDA)周五批准了Scholar Rock公司开发的SRRK.O疗法,用于治疗一种会导致肌肉无力的罕见遗传性疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4T4531I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","BK4588","IBRN","IE00B19Z9P08.USD","BK4533","LU0320765992.SGD","LU0234570918.USD","BMED","PBE","THNR","SRRK","LU0109394709.USD","BK4532","BK4139","IE00B894F039.SGD","LU0889565916.HKD","IE00B19Z9Z06.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666457170","title":"阿斯利康:SERENA-4臨床試驗未達到主要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666457170","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666457170?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:16","pubTimestamp":1789157801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBJ","IBBQ","MDTX","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666576453","title":"美國股市動態","url":"https://stock-news.laohu8.com/highlight/detail?id=2666576453","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666576453?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 01:49","pubTimestamp":1789148968,"startTime":"0","endTime":"0","summary":".N美国东部时间13:30,道琼斯工业平均指数.DJI上涨1.15%,报52,664.99点。标普500指数.SPX上涨1.07%,报7,673.08点;纳斯达克综合指数.IXIC上涨1.21%,报26,397.44点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4S4531CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDQ","PANW","SMR","QQQG","PMTS","SNDK","YARW","BDRX","RJF","STX","OKLL","WLDR","ONB","RENT","AGNG","TENB","ACVA","ATO","IXG","FLR","KR","CNAV","DELL","EXEL","SRFM","UCAR","CPRT","PTF","GME","HPE","BMED","KBWB","EW","MRNA","RKLB","HPQ","DLLL","TNON","RWT","IGV","AENT","SORCLmain","LHSW","ADBG","CIBR","FIZZ","ORCL","ADBE","OKLO","CHWY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2666544063","title":"興齊眼藥(300573.SZ):SQ-23082滴眼液獲批開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544063","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666544063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:54","pubTimestamp":1789113276,"startTime":"0","endTime":"0","summary":"智通财经APP讯,兴齐眼药(300573.SZ)发布公告,近日,公司收到国家药品监督管理局签发的关于SQ-23082滴眼液的《药物临床试验批准通知书》。SQ-23082滴眼液为公司研发的化学药品2.1类改良型新药。临床拟用于过敏性结膜炎相关的眼痒的治疗。根据改良型新药的有关要求,公司已经完成SQ-23082滴眼液药学及非临床药理毒理学等多方面的研究,研究结果表明SQ-23082滴眼液具有良好的安全性及临床开发价值。目前国内外尚无该眼用制剂产品上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK0239","PSYK","IBBJ","BMED","300573","BK0177","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666226544","title":"興齊眼藥:SQ-23082獲臨床試驗批准,屬2.1類","url":"https://stock-news.laohu8.com/highlight/detail?id=2666226544","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666226544?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:47","pubTimestamp":1789112862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","IBBQ","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666596063","title":"強生(JNJ)漲1.63% 新款雙周拋隱形眼鏡獲CE認證","url":"https://stock-news.laohu8.com/highlight/detail?id=2666596063","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666596063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 21:21","pubTimestamp":1789046500,"startTime":"0","endTime":"0","summary":"金吾财讯 | 强生(JNJ)美股盘前股价震荡上行,最新涨1.63%,报271.4美元。消息面上,强生周四宣布,旗下新款ACUVUE OASYS MAX双周抛复用隐形眼镜已拿到CE认证。该款产品属于ACUVUE OASYS MAX产品线的新品,可在完整14天佩戴周期内保障佩戴舒适度与清晰视力。镜片搭载OptiBlue滤光技术、TearStable锁泪技术以及一类紫外线防护功能,专门面向长时间使用电子屏幕人群的用眼需求设计。上市节奏方面,计划2026年晚些时候率先登陆部分欧洲国家;后续视各地监管审批进度,在2027-2028年进一步拓展市场。目前该产品尚未取得美国FDA批准,暂未在美国市场销售。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/OGNjYWRkOTg0ZTNhODNlYjIwMzU4Nzc5OGE1MjIxNzAyOTY4ODU1OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OGNjYWRkOTg0ZTNhODNlYjIwMzU4Nzc5OGE1MjIxNzAyOTY4ODU1OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305910","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","LU1066053197.SGD","IXJ","BK4581","JDOC","IE00BGHQF631.EUR","LU2750360997.AUD","LU1228905037.USD","PJP","LU0964807845.USD","IE00BDGV0183.EUR","VHT","LU1291159041.SGD","LU0345770993.USD","LU2750360641.GBP","FHLC","XLV","JNJ","BK4592","LU1732800096.USD","IHE","LU0124676726.USD","IE00BLSP4239.USD","LU1043141396.HKD","IE00BVYPNW00.USD","LU2756315664.SGD","LU2756315318.SGD","LU0792757196.USD","LU0070217475.USD","BMED","BK4559","GDOC","IE00BN8TJ469.HKD","SG9999001440.SGD","LU0689626769.HKD","LU1244550494.USD","LU2505996509.AUD","LU0820562030.AUD","FTXH","LU0820561909.HKD","TRUH","LU0345770308.USD","LU2133065610.SGD","MEDX","LU1929549753.HKD","BK4532","IYH","LU2456880835.USD","RXL","IE000BZT7R73.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666566579","title":"翰宇藥業(300199.SZ):HY3003注射液臨床試驗申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666566579","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666566579?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:21","pubTimestamp":1789028518,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰宇药业 发布公告,公司于近日收到国家药品监督管理局核准签发关于HY3003注射液临床试验申请的《受理通知书》。该项目通过人工智能结合多肽芯片技术筛选得到新型多肽分子,由翰宇药业负责临床前研究、IND申报及后续临床试验开发。HY3003拟用于减重、2型糖尿病、代谢相关脂肪性肝炎等适应症,是公司在代谢疾病领域布局的重磅创新药品种。HY3003项目是翰宇药业与碳云智肽在“AI+多肽”领域深度合作的典范。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","PSYK","BK0077","BMED","MDTX","IBBJ","BK0028","300199","BK0070","IBBQ","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666456659","title":"默沙東帕博利珠單抗三陰性乳腺癌適應症人群擴展在華獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2666456659","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666456659?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:21","pubTimestamp":1789028510,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1989772840.SGD","LU2491050071.SGD","LU0965509283.SGD","IE0009355771.USD","SG9999013999.USD","LU2361044865.SGD","LU0477156953.USD","LU0289739699.SGD","LU2023250504.SGD","LU0208291251.USD","LU0942090050.USD","IXJ","LU1162221912.USD","IE00BN8TJ469.HKD","TRUH","LU1066051498.USD","SG9999014575.USD","LU0234572021.USD","SG9999015358.SGD","LU1929549753.HKD","SG9999002224.SGD","LU0859254822.USD","LU1934455277.USD","PAWZ","LU0098860793.USD","LU0058720904.USD","LU0238689110.USD","LU1035773651.USD","LU0965508806.USD","LU1934455194.USD","LU1571399168.USD","LU1989772923.USD","LU2112291526.USD","LU2461242641.AUD","LU2361045086.USD","LU0265550946.USD","BK4516","LU0106261372.USD","SG9999001440.SGD","LU1201861249.SGD","LU0266013472.USD","LU1116320737.USD","LU1023059063.AUD","IE00BJT1NW94.SGD","LU2023250843.SGD","LU1923622614.USD","RXL","LU1917777945.USD","LU0861579265.USD","LU1585245621.USD","LU0211331839.USD","LU1061106388.HKD","BK4559","IE00BFTCPJ56.SGD","LU0432979614.USD","SG9999015341.SGD","SG9999014567.USD","IYH","LU1291159041.SGD","FTXH","LU1934455863.HKD","LU0868494617.USD","LU1941712348.USD","LU2125154778.USD","LU0130517989.USD","LU1066051225.USD","LU0122379950.USD","LU1037948897.HKD","IE00BLSP4452.SGD","LU1093756325.SGD","LU1032466523.USD","IHE","LU1989771016.USD","IE00BBT3K403.USD","LU0320765489.SGD","PPH","GDOC","SG9999014542.SGD","LU1057294990.SGD","JDOC","SG9999002232.USD","XLV","IE000M9KFDE8.USD","LU0070302665.USD","LU0868494708.USD","HRTS","LU2491049909.HKD","BK4533","BK4007","IE00BSNM7G36.USD","LU1983299246.USD","LU1116320901.HKD","IE0002141913.USD","LU2433249047.HKD","LU1066053197.SGD","LU1941712264.USD","LU0689626769.HKD","LU1066051811.HKD","LU0203347892.USD","LU0965509101.SGD","IE00B4R5TH58.HKD","BK4588","LU2360032135.SGD","LU1037948541.HKD","LU1093756168.USD","LU0965509010.AUD","LU0980610538.SGD","VHT","LU2089984988.USD","LU2361044949.HKD","BK4550","LU0124676726.USD","SG9999001176.USD","LU2125154935.USD","BMED","LU2357627491.SGD","LU0823416689.USD","LU0006306889.USD","LU1430594728.SGD","BK4534","IE00B1BXHZ80.USD","LU1699723380.USD","LU0648001328.SGD","LU0320765646.SGD","LU0130102774.USD","BK4585","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0265550359.USD","LU2106854487.HKD","LU1974910355.USD","LU2125909593.SGD","LU0985320562.USD","MRK","SG9999001176.SGD","LU0203345920.USD","LU1069347547.HKD","LU2324357040.USD","SGXZ57979304.SGD","LU2491050154.USD","LU2125909247.SGD","SG9999014559.SGD","LU2468319806.SGD","IE00BLSP4239.USD","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666565044","title":"翰宇藥業:HY3003注射液獲臨床試驗申請受理通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2666565044","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666565044?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:12","pubTimestamp":1789027978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBJ","PSYK","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555270","title":"英硅智能(03696):公司管線中領先的人工智能驅動候選創新藥物 Rentosertib已在針對特發性肺纖維化的III期臨床試驗中完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666555270?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 08:20","pubTimestamp":1788999632,"startTime":"0","endTime":"0","summary":"智通财经APP讯,英硅智能 发布公告,公司管线中领先的AI驱动候选创新药物 Rentosertib,已于北京协和医院完成III期临床试验的首例患者入组及给药;同日,上海市肺科医院亦完成了其在该试验的首例患者入组。GENESIS-IPF-3为一项评估Rentosertib用于特发性肺纤维化患者的III期临床试验。本试验旨在评估Rentosertib是否能比IIa期研究提供涵盖更大患者群体、且更长时间治疗的临床意义上的获益。Rentosertib透过抑制TNIK,旨在阻断或逆转纤维化进程,为IPF患者提供具备疾病改善潜力的治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["OGIG","PSQ","159992","MFIG","IBBQ","PSYK","NBDS","06978","TQQY","AIBU","NOCT","161631","QSWN","MVPS","GK","AGIX","CPNQ","AIQU","PBOT","CWC","KOMP","IBBJ","NEWZ","AQGX","TECY","CHAT","03696","ARTY","QQA","LNGR","GPIQ","BMED","VUSE","QMAR","TQQQ","QQQ","NJUL","QQQX","MDTX","TARK","DQJN","WPAI","MEDX","LCLG","QID","QTOC","AIFD","NJAN","FWD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580156","title":"拜耳啓動G蛋白偶聯內流整流鉀通道4研究性抑制劑針對心房顫動患者的II期臨床試驗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580156?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:42","pubTimestamp":1788954150,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBQ","MDTX","PSYK","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584416","title":"Leerink Partners上調默克目標價至161美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584416","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584416?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:22","pubTimestamp":1788949320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["SGXZ57979304.SGD","IE00BLSP4239.USD","LU1923622614.USD","RXL","IYH","LU1201861249.SGD","LU1430594728.SGD","UUP","GDOC","LU0868494708.USD","BMED","IXJ","LU0648001328.SGD","LU0965509283.SGD","LU2491049909.HKD","LU0689626769.HKD","MRK","IE00BJT1NW94.SGD","LU1066051225.USD","SG9999014542.SGD","SG9999014567.USD","PPH","IHE","LU2468319806.SGD","LU0980610538.SGD","LU1035773651.USD","LU1941712264.USD","LU2357627491.SGD","LU0965509101.SGD","LU0098860793.USD","PAWZ","FTXH","VHT","LU2125909247.SGD","LU2125909593.SGD","LU0203345920.USD","UDN","LU2106854487.HKD","SG9999015358.SGD","LU0234572021.USD","JDOC","TRUH","FHLC","HRTS","LU0122379950.USD","LU0238689110.USD","XLV","BK4534","SG9999013999.USD","LU1934455863.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}